New FDA-Approved Pill Potentially Doubles Pancreatic Cancer Survival Time

The FDA has officially approved Rasonque, a groundbreaking new daily pill that targets a specific genetic mutation to treat deadly pancreatic cancer. Medical experts say this massive breakthrough provides new hope for patients, with clinical trials showing the drug can double the average survival time.